Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$41,383
+$21,368 QoQ
Shares Held
1,609
+86.7% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#213
of 290 holders
Holding Since
Sep 2020
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Pacer Advisors, Inc. holds $626,865,233 across 140 Biotechnology names. DNLI ranks #62 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
369,451 | $230,367,476 | |
| 2 | INCY |
Incyte Corp
|
1,431,426 | $162,266,451 | |
| 3 | EXEL |
Exelixis, Inc.
|
1,096,682 | $59,670,467 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
72,465 | $35,995,539 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
146,264 | $35,245,236 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
506,545 | $28,984,504 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
228,060 | $17,850,256 | |
| 8 | HRMY |
Harmony Biosciences Holdings, Inc.
|
348,239 | $12,679,381 |
All Filings in DNLI
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $41,383 | 1,609 | Shares | Sole | 2026-08-13 | |
| 2024-06-30 | $20,015 | 862 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $41,553 | 2,025 | Shares | Sole | 2024-05-10 | |
| 2021-03-31 | $68,748 | 1,204 | Shares | Sole | 2021-04-05 | |
| 2020-12-31 | $138,706 | 1,656 | Shares | Sole | 2021-01-20 | |
| 2020-09-30 | $67,002 | 1,870 | Shares | Sole | 2020-10-19 | |
| No filing history on record for this holder in this stock. | ||||||